Answers are grounded in this paper and cite their sources.
Polyendocrine metabolic ovarian syndrome (PMOS), formerly polycystic ovary syndrome, is the commonest endocrine disorder of reproductive-age women, and circadian disruption is an established, modifiable exposure. Yet no single circadian gene replicates across granulosa-cell cohorts. We asked whether the circadian contribution is a distributed program rather than a portable gene panel. Six merged public microarray datasets underwent weighted gene co-expression network analysis, circadian-reference intersection, pathway enrichment and three-selector consensus feature selection. Two independent cohorts were tested within-cohort by differential expression, ROC and pre-ranked gene-set enrichment; a four-layer multi-omics dataset provided metabolic confirmation. A consensus panel (PPM1L, RNASE3, ZNF704) discriminated PMOS in discovery (cross-validated AUC 0.74, 95% CI 0.61–0.86). Out of cohort, a direction-consistent core (MAGED1, PPM1L and ZNF704 reduced; EDN1 raised) held in both, the core panel reaching AUC 0.80. Scored transcriptome-wide, the circadian-clock program was concordantly suppressed in both (meta-NES −1.82, adjusted p = 7.1 × 10⁻8), and ARNTL was down-regulated in the multi-omics dataset (p = 0.006) alongside NPAS2. ARNTL co-varied with glycolysis (ρ = 0.71) in cells with a dominant glycolytic–hypoxic program. PMOS granulosa cells therefore carry a distributed, direction-consistent suppression of the peripheral clock, coupled to glycolysis through the redox-sensitive factors NPAS2 and ARNTL.
No takes yet. Share an insight, caveat, or question.
Rajakumar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: